Kronos Bio (KRON) Projected to Post Earnings on Thursday

Kronos Bio (NASDAQ:KRON) is projected to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Kronos Bio to post earnings of ($0.30) per share and revenue of $1.00 million for the quarter.

Kronos Bio Trading Up 1.1 %

Shares of NASDAQ KRON opened at $0.95 on Tuesday. Kronos Bio has a 12-month low of $0.69 and a 12-month high of $1.60. The company has a market cap of $57.32 million, a P/E ratio of -0.66 and a beta of 1.79. The stock has a fifty day moving average price of $0.98 and a 200 day moving average price of $0.96.

Kronos Bio Company Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.